Halozyme Therapeutics (NASDAQ:HALO) Price Target Raised to $105.00

Halozyme Therapeutics (NASDAQ:HALO) had its price objective increased by research analysts at TD Cowen from $96.00 to $105.00 in a report issued on Friday,Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. TD Cowen’s price objective would indicate a potential upside of 1.82% from the stock’s current price.

HALO has been the subject of several other research reports. UBS Group reissued a “buy” rating and set a $90.00 price target on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. Wall Street Zen upgraded shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, May 16th. Wells Fargo & Company upped their price objective on shares of Halozyme Therapeutics from $75.00 to $95.00 and gave the company an “equal weight” rating in a research note on Friday. Morgan Stanley dropped their target price on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a report on Tuesday, May 12th. Finally, Leerink Partners upgraded Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and set a $110.00 price target on the stock in a report on Friday. Nine research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Halozyme Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $91.20.

Halozyme Therapeutics Trading Up 20.2%

Halozyme Therapeutics stock traded up $17.36 during trading hours on Friday, reaching $103.12. The company had a trading volume of 7,632,976 shares, compared to its average volume of 1,834,638. The company has a debt-to-equity ratio of 8.81, a current ratio of 2.76 and a quick ratio of 2.33. The company has a 50-day moving average price of $75.74 and a 200 day moving average price of $71.25. The firm has a market cap of $12.23 billion, a price-to-earnings ratio of 37.09, a P/E/G ratio of 0.35 and a beta of 0.85. Halozyme Therapeutics has a 12-month low of $61.22 and a 12-month high of $103.30.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, beating the consensus estimate of $1.79 by $0.49. The firm had revenue of $481.00 million during the quarter, compared to the consensus estimate of $402.28 million. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The business’s revenue was up 47.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.54 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Equities analysts forecast that Halozyme Therapeutics will post 7.54 earnings per share for the current year.

Insider Transactions at Halozyme Therapeutics

In related news, CEO Helen Torley sold 1,923 shares of the business’s stock in a transaction dated Wednesday, July 8th. The shares were sold at an average price of $79.77, for a total transaction of $153,397.71. Following the transaction, the chief executive officer owned 767,780 shares in the company, valued at $61,245,810.60. The trade was a 0.25% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mahesh Krishnan sold 7,304 shares of the stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $75.00, for a total transaction of $547,800.00. Following the completion of the transaction, the director directly owned 14,462 shares of the company’s stock, valued at approximately $1,084,650. The trade was a 33.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 72,477 shares of company stock valued at $5,102,643. Company insiders own 2.50% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Measured Wealth Private Client Group LLC lifted its position in Halozyme Therapeutics by 51.5% during the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 124 shares during the period. Abel Hall LLC boosted its holdings in shares of Halozyme Therapeutics by 4.2% during the 4th quarter. Abel Hall LLC now owns 3,216 shares of the biopharmaceutical company’s stock valued at $216,000 after buying an additional 129 shares in the last quarter. StoneX Group Inc. grew its position in shares of Halozyme Therapeutics by 3.8% in the 4th quarter. StoneX Group Inc. now owns 3,650 shares of the biopharmaceutical company’s stock worth $246,000 after buying an additional 132 shares during the period. Moran Wealth Management LLC grew its position in shares of Halozyme Therapeutics by 0.4% in the 4th quarter. Moran Wealth Management LLC now owns 35,596 shares of the biopharmaceutical company’s stock worth $2,396,000 after buying an additional 151 shares during the period. Finally, Twin Capital Management Inc. lifted its position in Halozyme Therapeutics by 1.4% during the 1st quarter. Twin Capital Management Inc. now owns 11,422 shares of the biopharmaceutical company’s stock valued at $738,000 after acquiring an additional 161 shares during the period. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Key Stories Impacting Halozyme Therapeutics

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Strong Q2 earnings beat: Halozyme reported adjusted earnings of $2.28 per share, versus the $1.79-$1.82 consensus range, while revenue rose 48% year over year to $481 million, well above the roughly $402 million estimate. Royalty revenue increased 50% to $308 million, highlighting continued momentum in the company’s ENHANZE platform. Halozyme Reports Record Second Quarter 2026 Results
• Positive Sentiment: Raised 2026 guidance: The company now expects revenue of $1.835-$1.910 billion, royalty revenue of $1.220-$1.245 billion, adjusted EBITDA of $1.225-$1.280 billion and non-GAAP EPS of $8.65-$9.00. The EPS outlook is above the prior consensus estimate of $8.02, signaling management’s confidence in sustained growth. Halozyme Q2 Earnings Beat Estimates
• Positive Sentiment: Business development exceeded expectations: Halozyme signed five new ENHANZE and Hypercon collaboration agreements year to date, already surpassing its full-year goal of three. These agreements could expand future royalty and licensing revenue.
• Positive Sentiment: Analyst support improved: Leerink Partners upgraded HALO to “outperform” with a $110 target, while HC Wainwright raised its target to $115 and maintained a “buy” rating.
• Neutral Sentiment: Citizens JMP raised its target to $93 and kept a “market outperform” rating; Wells Fargo lifted its target to $95 but maintained an “equal weight” rating. Both targets remain below the current trading level, indicating some analyst caution after the rally.
• Negative Sentiment: With HALO trading near its 52-week high, valuation and profit-taking risks may limit additional near-term gains despite the strong fundamental update.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.